Description

Thermo Fisher Scientific’s $1.6 Billion Acquisition Boost: Is Integration Paying Off?

Thermo Fisher Scientific reported its second quarter of 2026 with notable financial and operational performance across its diverse business segments. The company achieved a 10% increase in revenue to $11.99 billion, led by 5% organic growth, 5% contribution from recent acquisitions, and a minor foreign exchange tailwind. Adjusted operating income expanded by 15% to $2.73 billion, supported by a 90 basis point increase in adjusted operating margin to 22.8%. Adjusted earnings per share (EPS) rose 13% to $6.03. Geographically, growth was broad-based, with high single-digit increases in Europe and Asia Pacific, including low single-digit growth in China, and low single-digit growth in North America. Operational results were bolstered by strong performances across the pharmaceutical and biotech sectors, academic and government markets, industrial and applied markets, and diagnostics and health care businesses.